New Discoveries in Protein Methylation

A ground-breaking report from scientists at Glaxo and Epizyme has now revealed that the PRMT1 inhibitor, GSK3368715, exhibits potent anti-tumor activity. Extensive chemical and cellular studies support the usefulness of the new chemical compound as a First-In-Class therapeutic agent. Also described in the report are experiments that implicate the endogenous metabolic inhibitor, methyl-thioadenosine (MTA), in … Read more

Using E0771 Cells for Allograft Transplantation

After removing E0771 cells from cell culture using sterile technique, the cells are counted and injected into a healthy mouse via the mammary pads (typically the fourth mammary pad) or intravenously in the tail vein [1-8]. To see the full effects of tumor growth, 1 x 105 to 1 x 106 must be used for … Read more

Introduction to the E0771 Cell Line

E0771 is a mouse breast adenocarcinoma cell line. The original source of E0771 cells was a spontaneously occurring breast tumor from C57BL/6 mouse [1]. The tumor was removed from the breast fat pad of the mouse and adapted for anti‐cancer drug testing by Sirotnak et al. in 1984 [2]. Cell culture conditions as described in … Read more

Research Review Series (2 of 3)

THE INTERSECTION OF CANCER AND PROTEIN METHYLATION   William Pratt, CH3 Biosystems Lab Intern Introduction   Protein arginine methyltransferases (PRMTs) are transcriptional coactivators, a type of coregulator that affects a transcription factor to increase the rate of transcription of a gene by recruiting general transcription machinery to the promoter region. The aberrant expression of PRMTs … Read more

Research Review Series (1 of 3)

PRMT5 and Cancer  William Pratt, CH3 Biosystems Lab Intern   Protein methylation is a common post translational modification that has grown in importance as a research topic in recent years. The role of protein methylation in cancer is extremely complicated and thus very difficult to discuss broadly. This series of posts focuses on the relationship … Read more

Product Spotlight

PC12 Pheochromocytoma Cells     Advantage of PC12 Cells Every year thousands of people in the world are diagnosed with neurodevelopmental diseases and cancer. The need for better and more effective medications that can be brought to the market faster is on the rise. Each new drug is created from years of research and experiments … Read more

Research Spotlight

Methyltransferase Inhibitors Recent exciting news in the field of personalized medicine of cancer patients: new developments on the collaboration between Epizyme and GlaxoSmithKline may contribute the advancement of cancer treatment research tremendously.  Additionally, there has been new progress made by CH3 BioSystems to create a new drug discovery platform. New development on the collaboration between … Read more

Product Spotlight

Cell Lines Cell lines are derived from normal or diseased tissue that is disaggregated and subjected to limited dilution to generate one or a few cells. Therefore, after several dozen rounds of division, cultures of cell line consist of cells with uniform genetic make-up and additionally homogenous biochemical composition. Here at CH3 BioSystems, our cell lines are … Read more

Arginine methylation of RUNX1 affects peripheral CD4+ T cells in intact mice

Arginine methylation of RUNX1 affects peripheral CD4+ T cells in intact mice RUNX1 (previously termed AML1) is a frequent target of human leukaemia-associated gene aberrations, and it encodes the DNA-binding subunit of the Core-Binding Factor transcription factor complex. RUNX1 expression is essential for the initiation of definitive haematopoiesis, for steady-state thrombopoiesis, and for normal lymphocytes … Read more